Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMXI 5001

Next Previous
Search
Drug Profile

AMXI 5001

Alternative Names: AMXI-5001; Bifunctional PARP and microtubule polymerization inhibitor - AtlasMedx

Latest Information Update: 12 Aug 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AtlasMedx
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase 2 inhibitors; Poly(ADP-ribose) polymerase-1 inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Breast cancer; Cancer; Ovarian cancer

Highest Development Phases

  • Phase I/II Breast cancer; Cancer; Ovarian cancer

Most Recent Events

  • 12 Aug 2020 AMXI 5001 is available for licensing as of 12 Aug 2020. https://atlasmedx.com/
  • 30 Jul 2020 Phase-I/II clinical trials in Breast cancer (Late-stage disease, Second-line therapy or greater) in USA (PO) in July 2020 (NCT04503265)
  • 30 Jul 2020 Phase-I/II clinical trials in Cancer (Late-stage disease, Second-line therapy or greater) in USA (PO) in July 2020 (NCT04503265)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top